Prostate cancer: an evolving paradigm.
Abstract
Since at least the early 1990s, stage and risk migration have been seen in patients
with prostate cancer, likely corresponding to the institution of prostate specific
antigen (PSA) screening in health systems. Preoperative risk factors, including PSA
level and clinical stage, have decreased significantly. These improved prognostic
variables have led to a larger portion of men being stratified with low-risk disease,
as per the classification of D'Amico and associates. This, in turn, has corresponded
with more favorable postoperative variables, including decreased extraprostatic tumor
extension and prolonged biochemical-free recurrence rates. The advent of focal therapy
is bolstered by findings of increased unilateral disease with decreased tumor volume.
Increasingly, targeted or delayed therapies may be possible within the current era
of lower risk disease.
Type
Journal articleSubject
Biomarkers, TumorHumans
Male
Neoplasm Staging
Prostate-Specific Antigen
Prostatic Neoplasms
Risk Assessment
Risk Factors
Permalink
https://hdl.handle.net/10161/3242Published Version (Please cite this version)
10.1089/end.2009.0539Publication Info
Caso, Jorge R; Mouraviev, Vladimir; Tsivian, Matvey; Polascik, Thomas J; & Moul, Judd
W (2010). Prostate cancer: an evolving paradigm. J Endourol, 24(5). pp. 805-809. 10.1089/end.2009.0539. Retrieved from https://hdl.handle.net/10161/3242.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Judd Wendell Moul
James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of
Medicine
Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical
Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted
researcher and clinician in the area of prostate cancer and is a urologic oncologist.
He served as the division chief of Duke Division of Urology from 2004 to 2011 and
was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first
named endowed chair for urology. He was awarded the Gold Cystosco
Thomas James Polascik
Professor of Surgery
Prostate cancer imaging Focal therapy of prostate cancer Prostate cancer outcomes
Kidney cancer outcomes Minimally invasive surgery Nerve sparing cryotherapy
Matvey Tsivian
House Staff
Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info